Detailansicht

Wissensnetz

Person

Aysel Ahadova (1988-)

Name	Aysel Ahadova
Zeit	1988- (Lebensdaten)
Ort	Baku (Geburtsort) Heidelberg (Wirkungsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr. sc. hum. (an der Medizinischen Fakultät der Universität Heidelberg) (2015)
Variante	Aysel I. Ahadova
Beziehung	Klinikum Heidelberg Universität Heidelberg. Pathologisches Institut
Weitere Angaben	Tumorbiologie mikrosatelliten-intabiler (MSI) Tumoren, Angewandte Tumorbiologie, Pathologisches Institut, Universitätsklinikum Heidelberg
Datensatztyp	Person
GND-Nummer	106835268X
Datensatz-ID	106835268X
Beteiligt an alle anzeigen Tumour mutational burden: clinical utility, challenges and emerging improvements Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes - an EHTG, PLSD position statement Liquid biopsy-based early tumor and minimal residual disease detection: New perspectives for cancer predisposition syndromes Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers Correction to: The majority of β-catenin mutations in colorectal cancer is homozygous The majority of β-catenin mutations in colorectal cancer is homozygous Identification and management of Lynch syndrome in the Middle East and North African countries: outcome of a survey in 12 countries Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome Mechanisms of action of 2-deoxy-D-glucose in cancer cells and evaluation of novel approaches of application

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Aysel Ahadova (1988-)

Tumour mutational burden: clinical utility, challenges and emerging improvements

Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes - an EHTG, PLSD position statement

Liquid biopsy-based early tumor and minimal residual disease detection: New perspectives for cancer predisposition syndromes

Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers

Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium

Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers

Correction to: The majority of β-catenin mutations in colorectal cancer is homozygous

The majority of β-catenin mutations in colorectal cancer is homozygous

Identification and management of Lynch syndrome in the Middle East and North African countries: outcome of a survey in 12 countries

Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report

Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report

CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome

Mechanisms of action of 2-deoxy-D-glucose in cancer cells and evaluation of novel approaches of application